Senseonics Holdings, Inc. (NYSE: SENS), the developer of the Eversense 365 Continuous Glucose Monitoring (CGM) System, witnessed a significant surge in its stock price, soaring nearly 7% in pre-market trading on Wednesday.
The pre-market rally was fueled by the announcement of a software integration between Senseonics' Eversense 365 CGM system and SweetSpot, a virtual CGM monitoring platform. This collaboration allows endocrinology practices partnering with SweetSpot to seamlessly review and manage data from patients using Eversense 365, the world's first and only One Year CGM system.
The integration is expected to enhance patient care by enabling timely treatment adjustments based on regular CGM data reviews, ultimately improving glycemic control and patient outcomes. Additionally, it unlocks new revenue opportunities for healthcare providers through automated capture of reimbursable care events, making the partnership both clinically impactful and operationally efficient.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.